ResearcherAmrita Institute of Medical Sciences and Research CentreActive in the last 2 years
Kaladhar Kamalasanan
Matched on ORCID iD 0000-0002-3045-0753; OpenAlex author ID A5077936784.
Their work
- Papers
- 3 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Collaborators
- 4
2024: 1 paper · 2025: 1 paper · 2026: 1 paper
Papers 3
- Animal models to organoids for PK/PD studies of nanomedicines using advanced biomaterials for pancreatic cancer: A review. Last author DOI 10.1177/08853282261505008↗
- Bulk and surface engineered drug delivery system of repurposed drug enhances low-dose gemcitabine efficacy in pancreatic cancer. Co-author DOI 10.1016/j.ijpharm.2025.126152↗
- Pathophysiology-Driven Approaches for Overcoming Nanomedicine Resistance in Pancreatic Cancer. Co-author DOI 10.1021/acs.molpharmaceut.4c00801↗
Closest collaborators
The 4 strongest of 4 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Shona Sara Shaji · 1 shared paper, 2026
- M S Sithara · 2 shared papers, 2024–2025
- Paper Bulk and surface engineered drug delivery system of repurposed drug enhances low-dose gemcitabine efficacy in pancreati… DOI 10.1016/j.ijpharm.2025.126152↗
- Paper Pathophysiology-Driven Approaches for Overcoming Nanomedicine Resistance in Pancreatic Cancer. DOI 10.1021/acs.molpharmaceut.4c00801↗
- Sreejith Thrivikraman Nair · 2 shared papers, 2024–2025
- Paper Bulk and surface engineered drug delivery system of repurposed drug enhances low-dose gemcitabine efficacy in pancreati… DOI 10.1016/j.ijpharm.2025.126152↗
- Paper Pathophysiology-Driven Approaches for Overcoming Nanomedicine Resistance in Pancreatic Cancer. DOI 10.1021/acs.molpharmaceut.4c00801↗
- Thacho Sukumaran Mangalanandan · 1 shared paper, 2024
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.